"Antisickling Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
| Descriptor ID |
D000986
|
| MeSH Number(s) |
D27.505.954.502.135
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antisickling Agents".
Below are MeSH descriptors whose meaning is more specific than "Antisickling Agents".
This graph shows the total number of publications written about "Antisickling Agents" by people in this website by year, and whether "Antisickling Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 4 | 1 | 5 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antisickling Agents" by people in Profiles.
-
Riley C, Kraft WK, Miller R. Hydroxyurea in the sickle cell disease modern era. Expert Rev Clin Pharmacol. 2024 Sep; 17(9):777-791.
-
Rizk S, Axelrod DJ, Olaosebikan R, Ballas SK. Case Series and Review of Hematological and Non-Hematological Malignancies in Aging Patients with Sickle Cell Disease in the Hydroxyurea Era. Hemoglobin. 2020 Sep; 44(5):303-306.
-
Jabour SM, Beachy S, Coburn S, Lanzkron S, Eakin MN. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease. J Racial Ethn Health Disparities. 2019 12; 6(6):1233-1243.
-
Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2018 10 19; 10:CD003426.
-
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19; 379(3):226-235.
-
Parrow NL, Tu H, Nichols J, Violet PC, Pittman CA, Fitzhugh C, Fleming RE, Mohandas N, Tisdale JF, Levine M. Measurements of red cell deformability and hydration reflect HbF and HbA2 in blood from patients with sickle cell anemia. Blood Cells Mol Dis. 2017 06; 65:41-50.
-
Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2016 Mar 04; 3:CD003426.
-
Hayes MM, Vedamurthy A, George G, Dweik R, Klings ES, Machado RF, Gladwin MT, Wilson KC, Thomson CC. Pulmonary hypertension in sickle cell disease. Ann Am Thorac Soc. 2014 Nov; 11(9):1488-9.
-
Ballas SK, Martinez U, Savage M. Primary stroke in a woman with sickle cell anemia responsive to hydroxyurea therapy. Hemoglobin. 2014; 38(5):373-5.
-
Pulte ED, McKenzie SE, Caro J, Ballas SK. Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. Hemoglobin. 2014; 38(6):385-9.